论文部分内容阅读
肺孢子虫肺炎是接受免疫抑制化疗病人的主要并发症及死因之一,常见于急性淋巴细胞性白血病的持续缓解期。本文对160例癌肿患者(绝大多数为急性淋巴细胞性白血病患儿)随机分成治疗和对照两组,每组80例,以在化疗同时合用复方磺胺甲基异恶唑(TMP-SMZ)的为治疗组。经过2年的观察,统计并分析 TMP-SMZ 预防肺孢子虫肺炎的效果和长期应用的不良反应,及其对口、咽、胃肠道菌群的影响等。采取口服给药,混悬液每5毫升含 TMP40毫克和 SMZ200毫克;片剂的每片含量为 TMP80毫克和SMZ400毫克。剂量为 TMP150毫克及 SMZ750毫克/平方米/天,分为2次,间隔12小时。24小时内不超过 TMP320毫克和 SMZ1.6克,当体重变化>10%时,调整剂量。治疗组每例平均用药382天;对照组每例平均给
Pneumocystis pneumonia is one of the major complications and causes of death in patients receiving chemotherapy for immunosuppression, and is commonly found in persistent remission of acute lymphoblastic leukemia. In this paper, 160 cases of cancer patients (the vast majority of children with acute lymphoblastic leukemia) were randomly divided into treatment and control groups, 80 cases each in combination chemotherapy with sulfamethoxazole (TMP-SMZ) For the treatment group. After 2 years of observation, statistics and analysis of TMP-SMZ against Pneumocystis pneumonia and long-term adverse reactions, and its effects on the mouth, pharynx and gastrointestinal tract flora. Taken orally, the suspension contains TMP 40 mg and SMZ 200 mg every 5 ml; tablets each have TMP 80 mg and SMZ 400 mg. Dose TMP150 mg and SMZ750 mg / m2 / day, divided into two, an interval of 12 hours. Do not exceed TMP320 mg and SMZ1.6 g in 24 hours, adjust dose when body weight changes> 10%. Each treatment group average medication 382 days; the control group each give an average of